These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15852407)

  • 41. Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer.
    Yee D; Halperin R; Hanson J; Nijjar T; Butts C; Smylie M; Reiman T; Roa W
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):466-73. PubMed ID: 16563653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
    Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J
    Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy.
    Chauveinc L; Buthaud X; Falcou MC; Mosseri V; De la Rochefordière A; Pierga JY; Girodet J; Salmon RJ
    Br J Cancer; 2003 Dec; 89(11):2057-61. PubMed ID: 14647138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prophylactic cranial irradiation in limited-stage small-cell lung cancer: a retrospective analysis.
    Alshehadat S; Sahmoun AE
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):397-400. PubMed ID: 16163213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
    Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of small cell lung cancer in elderly.
    Satoh H; Ishikawa H; Funayama Y; Yamashita YT; Kamma H; Ohtsuka M; Sekizawa K
    Anticancer Res; 1999; 19(5C):4507-10. PubMed ID: 10650801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time factor in radiotherapy and chemotherapy for limited disease small-cell lung cancer.
    Nowara E; Suwinski R
    Cancer Invest; 2007; 25(3):163-71. PubMed ID: 17530486
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improving outcomes for limited stage small cell lung cancer patients in Scotland with concomitant chemoradiation.
    Law AB; Erridge SC; MacKean MJ; Kerr GR; Ironside JA; Little FA; Price A
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):188-93. PubMed ID: 17359905
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
    J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cisplatin-etoposide based chemoradiation treatment for limited small cell lung cancer: the current situation.
    Turrisi AT
    Anticancer Res; 1994; 14(1B):289-93. PubMed ID: 8166469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy.
    Semrau S; Klautke G; Virchow JC; Kundt G; Fietkau R
    Respir Med; 2008 Feb; 102(2):210-8. PubMed ID: 17980571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.
    Sekine I; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Kodama T; Saijo N
    Cancer Treat Rev; 2004 Jun; 30(4):359-68. PubMed ID: 15145510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of survival of patients with lung cancer between elderly (greater than or equal to 70) and younger (70 greater than) age groups.
    Kusumoto S; Koga K; Tsukino H; Nagamachi S; Nishikawa K; Watanabe K
    Jpn J Clin Oncol; 1986 Dec; 16(4):319-23. PubMed ID: 3025476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
    Wakelee HA; Stephenson P; Keller SM; Wagner H; Herskovic A; Komaki R; Marks RS; Perry MC; Livingston RB; Johnson DH;
    Lung Cancer; 2005 Jun; 48(3):389-97. PubMed ID: 15893008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.